Literature DB >> 16265403

Current management of locally advanced pancreatic cancer.

Vivek Maheshwari1, A James Moser.   

Abstract

Almost 30% of patients with pancreatic cancer present with large, locally advanced tumors in the absence of distant metastases. Because surgical resection is frequently contraindicated by vascular invasion, locally advanced pancreatic cancer has a dismal prognosis with a 6-10-month median survival. Recent advances in the multimodality treatment of other gastrointestinal malignancies have not altered the management of patients with locally advanced pancreatic cancer, a clinical dilemma reflected by the number of nonrandomized trials and anecdotal reports addressing this difficult disease. Our review summarizes the current status of aggressive surgical resection and neoadjuvant chemoradiation for locally advanced pancreatic cancer and suggests a treatment algorithm for patients with this disease based upon published clinical evidence.

Entities:  

Mesh:

Year:  2005        PMID: 16265403     DOI: 10.1038/ncpgasthep0240

Source DB:  PubMed          Journal:  Nat Clin Pract Gastroenterol Hepatol        ISSN: 1743-4378


  7 in total

1.  Inhibition of radiation-induced DNA repair and prosurvival pathways contributes to vorinostat-mediated radiosensitization of pancreatic cancer cells.

Authors:  Amit Deorukhkar; Shujun Shentu; Hee Chul Park; Parmeswaran Diagaradjane; Vinay Puduvalli; Bharat Aggarwal; Sushovan Guha; Sunil Krishnan
Journal:  Pancreas       Date:  2010-11       Impact factor: 3.327

2.  Effect of cromolyn on S100P interactions with RAGE and pancreatic cancer growth and invasion in mouse models.

Authors:  Thiruvengadam Arumugam; Vijaya Ramachandran; Craig D Logsdon
Journal:  J Natl Cancer Inst       Date:  2006-12-20       Impact factor: 13.506

3.  URG11 predicts poor prognosis of pancreatic cancer by enhancing epithelial-mesenchymal transition-driven invasion.

Authors:  Wei Peng; Jun Zhang; Jie Liu
Journal:  Med Oncol       Date:  2014-06-15       Impact factor: 3.064

4.  HER2 gene amplification and chromosome 17 copy number do not predict survival of patients with resected pancreatic adenocarcinoma.

Authors:  Saima Sharif; Ramesh K Ramanathan; Douglas Potter; Kathleen Cieply; Alyssa M Krasinskas
Journal:  Dig Dis Sci       Date:  2008-05-08       Impact factor: 3.199

5.  Patterns of self-reported symptoms in pancreatic cancer patients receiving chemoradiation.

Authors:  Cielito C Reyes-Gibby; Wenyaw Chan; James L Abbruzzese; Henry Q Xiong; Linus Ho; Douglas B Evans; Gauri Varadhachary; Samrat Bhat; Robert A Wolff; Christopher Crane
Journal:  J Pain Symptom Manage       Date:  2007-05-21       Impact factor: 3.612

Review 6.  Systematic review, including meta-analyses, on the management of locally advanced pancreatic cancer using radiation/combined modality therapy.

Authors:  A Sultana; C Tudur Smith; D Cunningham; N Starling; D Tait; J P Neoptolemos; P Ghaneh
Journal:  Br J Cancer       Date:  2007-04-03       Impact factor: 7.640

7.  Preoperative gemcitabine based chemo-radiotherapy in locally advanced non metastatic pancreatic adenocarcinoma.

Authors:  Doaa W Maximous; Mostafa E Abdel-Wanis; Mohammed I El-Sayed; Alaa A Abd-Elsayed
Journal:  Int Arch Med       Date:  2009-03-27
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.